Skip to main content
SpringerLink
Log in
Book cover

Alzheimer’s Disease pp 235–243Cite as

Neuroprotection and Neurodegenerative Disease

  • Chapter

  • 357 Accesses

Part of the book series: Current Clinical Neurology ((CCNEU))

Abstract

Genetic factors play a crucial role in the causation of Alzheimer’s disease (AD), with mutations in at least three genes responsible for early-onset familial AD. A common polymorphism in the apolipoprotein E (ApoE) gene is the major determinant of risk for families with late-onset AD, as well as the general population (1). Advanced age is another major risk factor, and environmental factors may influence disease expression. Some pathogenic factors include oxidative damage and mutations in messenger RNA (mRNA). Neuroprotective and multimodal therapies have not been explored yet.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Munoz, D.G.; Feldman, H.: Causes of Alzheimers disease. J Can Med Assoc 2000; 162: 65–76.

    CAS  Google Scholar 

  2. Torreiles, F.; Touchon, J.: Pathogenic theories and intrathecal analysis of the sporadic form of Alzheimer’s disease. Prog Neurobiol 2002; 66: 191–203.

    Article  Google Scholar 

  3. Ellison, D.; Love, S.: Neurodegenerative disorders. In: Ellison, D.; Love, S. (eds.): Neuropathology, a reference text of CNS pathology. Harcourt, London, 2000: 26. 1–33. 11.

    Google Scholar 

  4. Manji, H.K. et al.: Signaling pathways in the brain: cellular transduction of mood stabilization in the treatment of manic-depressive illness. ANZ J Psych 1999; 33: 565–583.

    Google Scholar 

  5. Vajda, F.J.E.: Valproate and neuroprotection. J Clin Neurosci 2002; 9: 508–514.

    Article  PubMed  CAS  Google Scholar 

  6. Hardy, J.; Gwinn-Hardy, K.: Genetic classification of primary neurodegenerative diseases. Science 1998; 282: 1075–1078.

    Article  PubMed  CAS  Google Scholar 

  7. Leist, M.; Nicotera, P.: Apoptosis, excitotoxicity and neuropathology. Exp Cell Res 1998; 239: 183–201.

    Article  PubMed  CAS  Google Scholar 

  8. Ellison, D.; Love, S.: Dementias. In: Ellison, D.; Love, S. (eds.): Neuropathology, a reference text of CNS pathology. Harcourt, London, 2000: 31. 1–31. 34.

    Google Scholar 

  9. Nicotera, P.; Lipton, S.A.: Excitotoxins in neuronal apoptosis and necrosis. J Cerebral Blood Flow Metab 1999; 19: 583–591.

    Article  CAS  Google Scholar 

  10. Montal, M.: Mitochondria, glutamate neurotoxicity and the death cascade. Biochim Biophys Acta 1998; 1366: 113–126.

    Article  PubMed  CAS  Google Scholar 

  11. Martin, L.J. et al.: Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998; 46: 281–309.

    Article  PubMed  CAS  Google Scholar 

  12. Olney, J.W.: Glutamate induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion. J Neuropathol Exp Neurol 1969; 28: 455–474.

    Article  PubMed  CAS  Google Scholar 

  13. Brown, G.K.; Squire, M.V.: Neuropathology and pathogenesis of mitochondrial diseases. J Inher Metab Dis 1996; 19: 553–572.

    Article  PubMed  CAS  Google Scholar 

  14. Lipton, S.A. et al.: Neuroprotective versus neurodestrnctive effects of NO-related species. Biofactors 1998; 8: 33–40.

    Article  PubMed  CAS  Google Scholar 

  15. Ludolph, A.C.; Meyer, T.; Riepe, M.W.: The role of excitotoxicity in ALS-what is the evidence? J Neurol 2000; 247 (suppl 1): 17–16.

    Article  Google Scholar 

  16. Arias, C.; Becerra-Garcia, F.; Tapia, R.: Glutamic acid and Alzheimer’s disease. Neurobiology 1998; 6: 33–43.

    PubMed  CAS  Google Scholar 

  17. Beal, M.F.: Mitochondria, free radicals and neurodegeneration. Curr Opin Neurobiol 1996; 6: 661–666.

    Article  PubMed  CAS  Google Scholar 

  18. Nichols, D.G.; Budd, S.L.: Neuronal excitotoxicity: the role of mitochondria. Biofactors 1998; 8: 287–299.

    Article  Google Scholar 

  19. Simpson, P.B.; Russell, J.T.: Role of mitochondrial Ca’ regulation in neuronal and glial cell signaling. Brain Res Rev 1998; 26: 72–81.

    Article  PubMed  CAS  Google Scholar 

  20. Ellison, D.; Love, S.: Alzheimers disease. In: Ellison, D.; Love, S. (eds.): Neuropathology, areference text of CNS pathology. Harcourt, London, 2000: 31. 1–31. 34.

    Google Scholar 

  21. Mattson, M.P.; Pedersen, W.A.: Effects of amyloid precursor protein derivatives and oxidative stress on basal forebrain cholinergic systems in Alzheimers disease. Int J Dev Neurosci 1998; 16: 737–753.

    Article  PubMed  CAS  Google Scholar 

  22. Blass, J.; Poirier, J.: Pathophysiology of the Alzheimer syndrome. In: Gauthier, S. (ed.): Clinical diagnosis and management of Alzheimer’s disease. Martin Dunitz, London, 1996: 17–31.

    Google Scholar 

  23. Mark, R.J. et al.: Anticonvulsants attenuate amyloid beta peptide neurotoxicity, Ca’ deregulation and cytoskeletal pathology. Neurobiol Aging 1995; 16: 187–198.

    Article  PubMed  CAS  Google Scholar 

  24. Lipton, S.A.: Similarity of neuronal cell injury and death in AIDS dementia and focal cerebral ischemia: potential treatment with NMDA open-channel blockers and nitric oxide-related species. Brain Pathol 1996; 6: 507–517.

    Article  PubMed  CAS  Google Scholar 

  25. Winblad, B. et al.: Pharmacothearpy of Alzheimer’s disease: is there a need to redefine treatment success? Intern J Geriatr Psychiatry 2001; 16: 653–666.

    Article  CAS  Google Scholar 

  26. Riekkinnen, P. Jr. et al.: Animal models in the development of symptomatic and preventive drug therapies for Alzheimer’s disease. Ann Med Finnish Med Soc 1998; 3: 566–576.

    Google Scholar 

  27. Huse, J.T.; Doms, R.W.: Neurotoxic traffic: uncovering the mechanics of amyloid production in Alzheimer’s disease. Traffic 2001; 2: 75–81.

    Article  PubMed  CAS  Google Scholar 

  28. Chapman. P. et al.: Genes, models and Alzheimer’s disease. Trends Genet 2001; 17: 254–261.

    Article  PubMed  CAS  Google Scholar 

  29. Golde, T.E.; Younkin, S.G.: Presenilins as therapeutic targets for the treatment of Alzheimer’s disease. Trends Molec Med 2001; 7: 264–269.

    Article  CAS  Google Scholar 

  30. Solo, C.: Plaque busters strategies to inhibit amyloid formation in Alzheimer’s disease. Molec Med Today 1999; 9: 343–359.

    Google Scholar 

  31. Vajda, F.J.E.: Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002; 9: 4–8.

    Article  PubMed  Google Scholar 

  32. Emre, M., Hanagasi, A.: Evidence based pharmacological treatment of dementia. Eur J Neurol 2000; 7: 247–253.

    Article  PubMed  CAS  Google Scholar 

  33. White, H.S.: Basic research update: evidence for neuroprotection with topiramate. Proc 3rd Ann Topamax Symposium, Satellite Meeting of Epilepsy Society of Australia, Annual Scientific Meeting, Adelaide, 1999.

    Google Scholar 

  34. Perucca, E.: A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35: 241–256.

    Article  PubMed  CAS  Google Scholar 

  35. Hanaya, R. et al.: Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res 1998; 789: 274–282.

    Article  PubMed  CAS  Google Scholar 

  36. Yang, Y. et al.: Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization. Brain Res 1998; 804: 169–176.

    Article  PubMed  CAS  Google Scholar 

  37. Macdonald, R.L.: Cellular actions of antiepileptic drugs. In: Eadie, M.J.; Vajda, F.J.E. (eds.): Antiepileptic drugs: pharmacology and therapeutics. Springer, Heidelberg/Berlin, Germany, 1999: 123–150.

    Chapter  Google Scholar 

  38. Meldrum, R.S.: Pharmacology and mechanism of action of lamotrigine. In: Reynolds, E.H. (ed.): Lamotrigine -a new advance in the treatment of epilepsy. Royal Society of Medicine Services, London, 1993: 5–10.

    Google Scholar 

  39. Walker, M.C.; Sander, J.W.A.S.: Lamotrigine. In: Eadie, M.J.; Vajda, F.J.E. (eds.): Antiepileptic drugs: pharmacology and therapeutics. Springer, Heidelberg/Berlin, Germany, 1999: 331–358.

    Chapter  Google Scholar 

  40. Loscher, W.: Valproate: a reappraisal of its pharmacodynamic properties and mechanism of action. Prog Neurobiol 1999; 58: 31–59.

    Article  PubMed  CAS  Google Scholar 

  41. Manji, H.K.; Moore, G.J.; Chen, G.: Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive disorders. Biol Psychiatry 2000; 48: 740–754.

    Article  PubMed  CAS  Google Scholar 

  42. Moore, G.J. et al.: Lithium-induced increase in human brain grey matter. Lancet 2000; 356: 1241–1242.

    Article  PubMed  CAS  Google Scholar 

  43. Motohashi, N.: Valproate for the treatment of psychiatric disorders. Jpn J Neuropsychopharmacol 2001; 72: 879–882.

    Google Scholar 

  44. Manji, H.K. et al.: Neuroplasticity and cellular resilience in mood disorders. Molec Psychiatry 2000; 5: 578–593.

    Article  CAS  Google Scholar 

  45. Manji, H.K.; Moore, G.J.; Chen, G.: Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilizers. Br J Psychiatry 2001; 178 (suppl 41): 107–119.

    Article  Google Scholar 

  46. Chen, G. et al.: The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bc1–2 in the CNS. J Neurochem 1999; 72: 879–882.

    Article  PubMed  CAS  Google Scholar 

  47. Eriksson, P.S. et al.: Neurogenesis in the adult hippocampus. Nat Med 1998; 4: 1313–1317.

    Article  PubMed  CAS  Google Scholar 

  48. Kempermann, G.; Gage, F.H.: Experience-dependent regulation of adult hippocampal neurogenesis: effects of long term stimulation and stimulus withdrawal. Hippocampus 1999; 9: 321–332.

    Article  PubMed  CAS  Google Scholar 

  49. Ellison, D.; Love, S.: Parkinson’s disease. In: Ellison, D.; Love, S. (eds.): Neuropathology, areference text of CNS pathology. Harcourt, London, 2000: 28. 1–28. 16.

    Google Scholar 

  50. Jenner, P.; Olanow, C.W.T.: Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 1996; 47 (suppl 3): 5161–5170.

    Google Scholar 

  51. Langston, J.W.: The etiology of Parkinson’s disease with emphasis on the MPTP story. Neurology 1996; 47 (suppl 3): S 153-S 160.

    Google Scholar 

  52. Gerlach, M.; Youdim, M.B.H.; Reiderer, P.: Pharmacology of selegiline. Neurology 1996; 47 (suppl 3): 5137–5145.

    Google Scholar 

  53. Tatton, W.G.; Chalmers-Redman, R.M.: Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration. Neurology 1996; 47 (suppl 3): 5171–5183.

    Google Scholar 

  54. Olanow, C.W.: Selegiline: current perspectives on issues related to neuroprotection and mortality. Neurology 1996; 47 (suppl 3): 5210–5216.

    Google Scholar 

  55. Birks, J.; Flicker, L.: Selegiline for Alzheimer’s disease. The Cochrane Database of Systematic Reviews 1 (2001).

    Google Scholar 

  56. McGeer, P.L.; Rogers, J.; McGeer, E.G.: Neuroimmune mechanisms in Alzheimer disease pathogenesis. Alz Dis Assoc Disord 1994; 8: 149–158.

    Article  CAS  Google Scholar 

  57. Eikelenboom, P. et al.: Inflammatory mechanisms in Alzheimer’s disease. Trends Pharmacol Sci 1994; 15: 447–450.

    Article  PubMed  CAS  Google Scholar 

  58. Jenkinson, M.L. et al.: Rheumatoid arthritis and senile dementia of the Alzheimer’s type. Br J Rheumatol 1989; 28: 86–88.

    Article  PubMed  CAS  Google Scholar 

  59. Broe, G.A. et al.: A case-control study of Alzheimer’s disease in Australia. Neurology 1990; 40: 1698–1707.

    Article  PubMed  CAS  Google Scholar 

  60. McGeer, P.L. et al.: Anti-inflammatory drugs and Alzheimer disease. Lancet 1990; 335: 1037.

    Article  PubMed  CAS  Google Scholar 

  61. Breitner, J.C. et al.: Inverse association of anti-inflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44: 227–232.

    Article  PubMed  CAS  Google Scholar 

  62. The Canadian Study of Health and Aging. Risk factors from Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–2080.

    Article  Google Scholar 

  63. Andersen, K. et al.: Do non steroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease. The Rotterdam Study. Neurology 1995; 45: 1441–1445.

    Article  PubMed  CAS  Google Scholar 

  64. Rich, J.B. et al.: Non-steroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995; 45: 51–55.

    Article  PubMed  CAS  Google Scholar 

  65. Breitner, J.C.S. et al.: Alzheimer’s disease in the NAS-NRC Registry of aging twin veterans. II. Longitudinal findings in a pilot series. National Academy of Sciences/National Research Council Registry. Dementia 1994; 5: 99–105.

    PubMed  CAS  Google Scholar 

  66. Lipsky, P.E.: Clinical potential of cyclooxygenase-2 specific inhibitors. Am J Med 1999; 106: S51 - S57.

    Article  Google Scholar 

  67. Sainali, S.M. et al.: Results of a double-blind placebo controlled trial of celecoxib in the treatment of the progression of Alzheimer’s disease. 6th Stockholm Springfield Symposium of Advances in Alzheimer Therapy, April 2000.

    Google Scholar 

  68. Dannhardt, G.; Kiefer, W.: Cyclooxygenase inhibitors current status and future prospects. Eur J Med Chem 2001; 36: 109–126.

    Article  PubMed  CAS  Google Scholar 

  69. McGeer, P.: Cyclo-oxygenase-2-inhibitors. Drugs Aging 2000; 17: 1–11.

    Article  PubMed  CAS  Google Scholar 

  70. Rogers, J. et al.: Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–1611.

    Article  PubMed  CAS  Google Scholar 

  71. Scharf, S. et al.: A double-blind placebo-controlled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53: 197–201.

    Article  PubMed  CAS  Google Scholar 

  72. Garcia-Seguar, L.M.; Azcoitia, I.; Don Carlos, L.L.: Neuroprotection by estradiol. Prog Neurobiol 2001; 63: 29–60.

    Article  Google Scholar 

  73. Monk, D.; Brodaty, H.: Use of estrogens for the prevention and treatment of Alzheimer’s disease. Dement Geriatr Cognit Disord 2000; 11: 1–10.

    Article  CAS  Google Scholar 

  74. Fillit, H. et al.: Observations in a preliminary open trial of estradiol therapy for senile dementia Alzheimer type. Psychoneuroendocrinology 1986; 11: 337–345.

    Article  PubMed  CAS  Google Scholar 

  75. Henderson, V.W. et al.: Estrogen replacement therapy in older women. Comparison between Alzheimer’s disease cases and non-demented control subjects. Arch Neurol 1994; 51: 896–900.

    Article  PubMed  CAS  Google Scholar 

  76. Costa, M.M. et al.: Estrogen replacement therapy and cognitive decline in memory-impaired post-menopausal women. Biol Psychiatry 1999; 46: 182–188.

    Article  PubMed  CAS  Google Scholar 

  77. Van Amelsvooert, T.; Compton, J.; Murphy, D.: In vivo assessment of the effects of estrogen on the human brain. Trends Endocrinol Metab 2001; 12: 273–275.

    Article  Google Scholar 

  78. Panidis, K.D. et al.: The role of estrogen replacement therapy in Alzheimer’s disease. EurJ Obstet Gyn Reprod Biol 2001; 95: 86–91.

    Article  CAS  Google Scholar 

  79. Wiltfang, J. et al.: Molecular biology of Alzheimer’s dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology 2001; 47: 65–71.

    Article  PubMed  CAS  Google Scholar 

  80. Giulian, D.: A strategy for identifying immunosuppressive therapies for Alzheimer disease. Alz Dis Assoc Disord 1998; 12 (suppl 2): S7 — S14.

    Article  CAS  Google Scholar 

Download references

Authors
  1. Frank John Emery Vajda
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The University of Oklahoma College of Medicine, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  2. Alzheimer’s Disease Research Unit, St. John Medical Center, Tulsa, OK, USA

    Ralph W. Richter MD, FACP (Clinical Professor of Neurology and Psychiatry, Director) (Clinical Professor of Neurology and Psychiatry, Director)

  3. Tulsa, OK, USA

    Brigitte Zoeller Richter DiplPharm (Pharmacist, Publicist) (Pharmacist, Publicist)

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Vajda, F.J.E. (2004). Neuroprotection and Neurodegenerative Disease. In: Richter, R.W., Richter, B.Z. (eds) Alzheimer’s Disease. Current Clinical Neurology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-661-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-661-4_27

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4485-9

  • Online ISBN: 978-1-59259-661-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation